section name header

Pronunciation ⬇

fi-dax-oh-MYE-sin

Classifications ⬆ ⬇

Therapeutic Classification: anti-infectives

Pharmacologic Classification: macrolides

Indications ⬆ ⬇

REMS


Action ⬆ ⬇

  • Bactericidal action mostly against clostridia; inhibits RNA synthesis.
  • Acts locally in the GI tract to eliminate Clostridioides difficile.
Therapeutic effects:
  • Elimination of diarrhea caused by Clostridioides difficile.

Pharmacokinetics ⬆ ⬇

Absorption: Minimal systemic absorption.

Distribution: Stays primarily in the GI tract.

Metabolism/Excretion: Mostly transformed via hydrolysis in the GI tract to OP-1118, its active metabolite. Eliminated mostly (>92%) in feces: <1% excreted in urine.

Half-Life: Fidaxomicin: 11.7 hr; OP-1118: 11.2 hr.

Time/Action Profile ⬆ ⬇

ROUTEONSETPEAKDURATION
POunknownunknownunknown



Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆

Dificid